ClinicalTrials.gg
Active, not recruitingNCT02405676BNHL-2015Updated Mar 19, 2026

BNHL-2015 for Children or Adolescents in China

A Phase 2/3 interventional study of Prednisone,Vincristine, Cyclophosphamide and Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone in Mature B-cell Non-Hodgkin Lymphoma, sponsored by Children's Cancer Group, China. Active, not recruiting at 1 site in China. Open to participants aged Up to 16 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Children's Cancer Group, China · Phase 2/3, Interventional, and Treatment

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
Up to 16 Years
Sex
All
01

Study summary

The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.

Read the detailed description

In our previous study (CCCG-NHL-2010), two-year EFS was 100% for Stage I, 91.3% ± 6.1% for Stage II, 75.8% ± 4.4% for Stage III, 56.3% ± 13.5% for Stage IV, and 36.4% ± 14.5% for B-AL, respectively. To improve survival for pediatric patients with B-NHL/B-AL, the investigators launched a new study in China. Compared with our previous treatment regimens (CCCG-2010), patients with stage III and LDH>4 times NL, any stage IV or B-AL were stratified into R4. The dose of methotrexate was increased to 5000mg/m2 for patients in R3 or R4 (previously 3000mg/m2). Four injections of rituximab was added to the chemotherapy for patients in R4. Our aim is to test whether adding rituximab or high dose of methotrexate (5000mg/m2) would improving 2-year EFS for patients in advanced groups.

02

Conditions studied

  • Mature B-cell Non-Hodgkin Lymphoma

Browse trials for

Keywords

  • Lymphoma
  • non-Hodgkin
  • B-lymphocytes
  • Child
  • Multicenter study
03

In context

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

This study's planned enrollment of 200 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Children's Cancer Group, China is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Histology or confirmed matureB-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
  • Able to comply with scheduled follow-up and with management of toxicity
  • Signed

Exclusion Criteria:

  • Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
  • Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous of any type, or known positive serology.
  • -Evidence of pregnancy or lactation period.

    • Past or current anti-cancer treatment except during less than one week.

Exclusion criteria related to rituximab:

  • Tumor cell negative for CD20.
  • Prior exposure to rituximab.
  • carrier status history of HBV or positive serology.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Risk group 1

    Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);

    Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone · Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone

  • Other
    Risk group2

    Not or incompletely resected stage I/II disease and LDH \<2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;

    Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone · Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone

  • Other
    Risk group3

    Stage III with high LDH \< 4 times NL, or Stage I,II with LDH \>=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.

    Drug: Prednisone,Vincristine, Cyclophosphamide · Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone · Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone · Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone

  • Other
    Risk group4

    Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.

    Drug: Prednisone,Vincristine, Cyclophosphamide · Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone · Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone · Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone · Drug: Rituximab

Interventions

  • DrugPrednisone,Vincristine, Cyclophosphamide

    Drug pages: Prednisone · Vincristine · Cyclophosphamide

    Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;

    Also known as: Preface

  • DrugCyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone

    Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

    Also known as: Protocol A

  • DrugIfosphamide, Etoposide, Methotrexate, Vincristine, Prednisone

    Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

    Also known as: Protocol B

  • DrugCyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone

    Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

    Also known as: Protocol AA

  • DrugIfosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone

    Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

    Also known as: Protocol BB

  • 375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;

06

What researchers measure

Primary outcomes

  1. Event free survival

    Time frame: 2 year

Secondary outcomes

  1. Overall survival

    Time frame: 5 year

07

Study locations

1 site
08

References and documents

Publications

  • Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol. 2012 Mar;156(6):730-43. doi: 10.1111/j.1365-2141.2011.09024.x. Epub 2012 Jan 20. PubMed 22260323 ↗
  • Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Muller-Weihrich S, Pluss HJ, Zintl F, Henze G, Riehm H. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999 Nov 15;94(10):3294-306. PubMed 10552938 ↗
  • Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005 Feb 1;105(3):948-58. doi: 10.1182/blood-2004-03-0973. Epub 2004 Oct 14. PubMed 15486066 ↗
  • Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Munster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010 Jul 1;28(19):3115-21. doi: 10.1200/JCO.2009.26.6791. Epub 2010 Jun 1. PubMed 20516455 ↗
  • Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3. No abstract available. PubMed 22940833 ↗
  • Gao YJ, Fang YJ, Gao J, Yan J, Yang LC, Liu AG, Ju XL, Lu J, Han YL, Wang J, Xie M, Guo X, Tang JY. A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children's Cancer Group. Ann Hematol. 2022 Sep;101(9):2035-2043. doi: 10.1007/s00277-022-04904-w. Epub 2022 Jul 13. PubMed 35829780 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2015 to primary completion in Dec 2023, 107 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2015
First posted
Apr 1, 2015
StartActual
Jan 1, 2015
Primary completionActual
Dec 31, 2023
CompletionEst.
Dec 2029
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02405676
Lead sponsor
Children's Cancer Group, China
Collaborators
Tongji Hospital, Nanjing Children's Hospital, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Children's Hospital of Soochow University, Tianjin Medical University Cancer Institute and Hospital
Responsible party
Yi-Jin Gao (Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China, Children's Cancer Group, China) — Principal investigator
First posted
Apr 1, 2015
Start date
Jan 1, 2015
Primary completion
Dec 31, 2023
Completion
Dec 2029 (estimated)
Last update
Mar 19, 2026

Study contacts

Yi-Jin Gao, MD
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisone · Vincristine · Cyclophosphamide · Rituximab

Start the discussion